ContraFect to Present CF-301 Phase 1 Trial Data at the 26th

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ContraFect to Present CF-301 Phase 1 Trial Data at the 26th ECCMID Conference

YONKERS, NY --(Marketwired - March 29, 2016) - ContraFect Corporation   (NASDAQ: CFRX) ( NASDAQ : CFRXW ), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that it will present new clinical data from a Phase 1 clinical trial of CF-301 at the 26 th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) to be held on April 9-12, 2016 in Amsterdam.

"This is an exciting time for ContraFect as well as the lysin field, as we have successfully concluded the first in human trial of CF-301, a first in class lysin drug candidate," said Steven C. Gilman, PhD, Chairman and CEO of ContraFect. "We are now expeditiously moving towards the next phase of development of CF-301, which will be in patients with Staph aureus bacteremia."

"We are pleased that CF-301 was generally well tolerated and that there were no clinical adverse safety signals identified in this Phase 1 study. Pharmacokinetic (PK) parameters were linear across the 4 doses tested," said Cara Cassino, M.D., Chief Medical Officer of ContraFect. " Staph aureus infections continue to result in substantial morbidity and mortality despite available therapies. CF-301 in combination with conventional standard of care antibiotics has the potential to improve clinical outcomes in patients with Staph aureus infections."

Study Results

This CF-301 Phase 1 study was a single-center, double-blind, randomized, placebo-controlled, escalating, single-dose study in healthy male and female subjects. CF-301 or placebo were administered via 2-hour IV infusion at 4 CF-301 dose levels: 0.04, 0.12, 0.25, and 0.4 mg/kg/dose. Subjects remained in the clinic from days -1 to 4. Serial blood and urine samples were collected for clinical laboratory tests and PK. Safety assessments included physical exams, vital signs, 12-lead EKGs, Holter monitoring/telemetry, and adverse events (AE). Subjects returned on days 5, 8, 14 and 28 for follow-up safety evaluation. All subjects were tested for anti-drug antibodies (ADA), immunoglobulin E (IgE), and ex vivo basophil activation (BAT) on Days -1, 5, 8, 14 and 28 and at ongoing long-term follow-up visits (days 90 and 180). Subjects with pre-existing positive readings for any of these tests during screening were excluded from the trial. An independent Data Safety Monitoring Board (DSMB) reviewed unblinded safety and PK data at pre-specified points throughout the study.

Subjects were dosed at each of the 4 planned dose levels, for a total of 20 subjects. There were no serious AEs, and no study stopping rules were met. In addition, no hypersensitivity AEs related to CF-301 were observed. A total of 5 non-serious AEs were reporting during the study. Two subjects who received CF-301 reported a total of three non-serious AEs (headache, contact dermatitis, and allergic rhinitis). Two subjects who received placebo reported a total of two non-serious AEs (viral upper respiratory tract infection and viral infection). All of these events were mild in intensity and resolved. No patients withdrew from the study for an adverse event. At the 0.25 mg/kg dose, the geometric mean (gMean) CF-301 AUC (inf) was 1,758 hr x ng/mL, and the gMean C max was 731 ng/mL. Exposure was dose dependent and intra-subject variability was low. Estimated effective exposure, based on animal models of Staph aureus infections, was attained at the 0.25mg/kg dose.

The abstract on this data can be found on the ECCMID website ( http://www.eccmid.org/ ). ContraFect's presentation information is as follows:

Abstract Title: Results of the First-in-Human Study of Lysin CF-301 Evaluating the Safety, Tolerability, and Pharmacokinetic (PK) Profile in Healthy Human Volunteers

Session Title: Late breaker ePoster

Session Day and Time: April 9, 2016, 8:45-15:30 CET

Abstract #: EVLB62

About CF-301:

CF-301 is a recombinant bacteriophage-derived lysin with potent, bactericidal, activity against Staphylococcus aureus ( Staph aureus ), a major cause of blood stream infections, or bacteremia. CF-301 has the potential to be a first-in-class treatment for Staph aureus bacteremia as it has a novel, rapid and specific mechanism of bactericidal action against Staph aureus and does not impact the body's natural bacterial flora. By targeting a conserved region of the cell wall that is vital to bacteria, resistance is less likely to develop to CF-301. Combinations of CF-301 with standard of care antibiotics significantly increased bacterial killing and survival in animal models of disease when compared to treatment with antibiotics or CF-301 alone. In addition, in vitro and in vivo experiments have shown that CF-301 is highly active against biofilm infections. CF-301 was licensed from The Rockefeller University and is being developed at ContraFect.

About ContraFect:

ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (drug-resistant Staph aureus bacteria) and influenza.

FORWARD-LOOKING STATEMENTS

This press release contains, and our officers and representatives may make from time to time, "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "new", "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipate," "estimates," "intends," "plans," "potential," "promise" or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding the presentation of our Phase 1 clinical trial data, our ability to move towards our next phase of CF-301 development, the ability of CF-301 in combination with conventional standard of care antibiotics to provide improved clinical outcomes in patients with Staph aureus infections, our CF-301 Phase 1 study results, the potential for CF-301 to be a first in class treatment for Staph aureus and ContraFect's ability to discover and develop therapeutic protein and antibody products for life-threatening, drug resistant infectious diseases. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect's current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect's control, including those detailed in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations Contact Paul Boni ContraFect Corporation 914-207-2300 pboni@contrafect.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 225

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
24X Options Filing Puts Earnings Bets Before the SEC

Updated Category News Views 71

An earnings release already turns the market into a bar fight; 24X wants to put part of that fight inside a regulated binary-options contract. The Stamford-based exchange has filed a proposed rule change with the SEC for 24X Options, a facility that would offer a conventional options market alongside contracts tied to company performance targets. It is an interesting...

Continue Reading
Utility Global’s India Steel Move Needs Hard Numbers

Updated Category News Views 114

Steel decarbonization announcements can sound enormous before a single bolt gets tightened. Utility Global says it plans to deploy its first industrial H2Gen project in India with Tata Steel, and that is plainly worth watching. Tata Steel is a serious industrial name, India is a consequential steel market, and any technology that can credibly lower emissions from heavy...

Continue Reading
Paladone Tests LEGO's Everyday Collectibles Pull Abroad

Updated Category News Views 71

A glowing minifigure lamp is not exactly a macroeconomic event, but licensed merchandise has a funny way of revealing where household spending still has a pulse. Paladone Products has put its first LEGO-branded collection into stores, a modest-looking launch with some real retail logic behind it. This is not a grand toy-box bet on one blockbuster item. It is a spread of...

Continue Reading
Texas Restaurants Get a New Read on Customer Demand

Updated Category News Views 88

Texas restaurant owners are being handed a sharper flashlight, and frankly it is overdue. HundredX and the Texas Restaurant Association have launched a pilot that gives TRA members access to the HundredX Restaurant Insights Platform, aiming to bring customer and market intelligence to the independent operators and regional chains that usually cannot pay big-company prices...

Continue Reading
Tonum and Euvita Link Supplements to Personalized Care

Updated Category News Views 8

Muscle loss has become the awkward footnote in the GLP-1 weight-loss boom, and Tonum Health is trying to put that concern nearer the center of the care conversation. Its newly announced partnership with euvita health places Tonum's supplements and functional nutrition products inside a physician-led platform built around biomarker testing, hormone and peptide therapy,...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 83

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
Qonto's Banking License Raises the Stakes in Europe

Updated Category News Views 70

A regulatory stamp can look dull on paper, yet this one changes the machinery underneath Qonto. The Paris-based finance platform has received a Credit Institution license from France's ACPR and the European Central Bank, giving it a route to offer broader lending and savings products directly to small and midsize businesses across Europe. That is a serious corporate...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 296

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
APEC's Shared-Prosperity Message Needs More Detail

Updated Category News Views 20

Geese make handsome symbols, but markets cannot underwrite a metaphor. The Nov. 18, 2026 report from Xinhua News Agency looks back to remarks Chinese President Xi Jinping made 12 years ago, when he used swan geese to urge APEC economies toward greater cooperation and a new collective flight. Its present-day message is plainly hopeful: the APEC family is moving across the...

Continue Reading

Top 5 Most Recently Viewed Articles

Therap Services Implements SMS Security Features for Users

Updated Category News Views 172

Enhancing Security and User Control with SMS Features Therap Services is at the forefront of improving data protection in the realm of electronic documentation solutions specifically tailored for the Long-Term Services and Supports (LTSS) and Home and Community-Based Services (HCBS). By recently rolling out SMS-based password reset and two-factor authentication (2FA)...

Continue Reading
Understanding Stakeholder Disclosures in Student Property Sector

Updated Category News Views 127

Key Insights into Stakeholder Disclosure Regulations Stakeholder disclosures play a crucial role in maintaining transparency in the market, particularly in industries like real estate and student accommodations. Understanding these requirements is essential for investors and companies alike. This discussion focuses on the significance of disclosures concerning relevant...

Continue Reading
VestGen Wealth Partners Expands Leadership for Enhanced Services

Updated Category News Views 130

VestGen Expands Leadership Team to Elevate Client Services In a strategic move aimed at enhancing its operations and service offerings, VestGen Wealth Partners, LLC has announced a significant expansion of its leadership team. This includes the appointment of Rob Bondiman as the National Head of Advisors and Matt LaLonde as the inaugural Director of Insurance, heading...

Continue Reading
Toll Brothers Launches Stunning New Townhome Community

Updated Category News Views 304

Introducing Toll Brothers at East Cobb Walk Toll Brothers, Inc., renowned for its premium housing, has unveiled its new community, now available for sale. This exciting release presents a rare opportunity for homebuyers to invest in beautiful townhomes within an attractive neighborhood. Luxury Townhomes with Modern Designs The new community, Toll Brothers at East Cobb...

Continue Reading
Understanding Assura Plc's Recent Public Disclosure

Updated Category News Views 129

Public Disclosure Overview Understanding public disclosures is crucial for investors and stakeholders in the financial market. In this article, we will explore Assura Plc's latest public disclosure under Rule 8.3 of the Takeover Code. The company revealed significant information about interests that represent over 1% of certain securities. These disclosures aim to provide...

Continue Reading